DPFS Resource Request (Cardiff University/Bristol University SARTRE):A core protein production facility

Lead Research Organisation: Cardiff University
Department Name: School of Medicine

Abstract

There is an essential need for new treatments to fight infectious and inflammatory diseases. This proposal will provide essential core facilities that will allow scientific discoveries to be more rapidly realized in clinical treatments. One of the problems in drug development is the amount of time to bring a scientific idea to the clinic. By centralizing resources across the cardiff/Bristol Alliance this should allow researches in both universities to engage in more collaboration and thereby more rapidly take ideas and realize them as novel treatments.

Technical Summary

The current application seeks funding to support the establishment of a core protein production facility that will support the translational objectives of the Cardiff University/Bristol University Severnside strategic alliance (SARTRE). Based within the existing core facilities portfolio at cardiff University, School of Medicine (Central Biotechnology Services) this protein production facility will address a significant bottleneck in progressing protein and peptide-based therapeutics through the translational pipeline by providing medium scale rapid production (to pre-GMP standard) of high purity proteins for early and late phase proof-of-concept studies. It will thus provide a central resource across the Severnside Alliance that will underpin current and significantly facilitate the development of therapeutics and diagnostic in our identified areas of research excellence.

Publications

10 25 50
 
Description Core Facilities
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
 
Description A feasibility study into Central Biotechnology Services (CBS) becoming an accredited Knowledge Transfer Centre
Amount £14,998 (GBP)
Organisation Health and Care Research Wales 
Sector Public
Country United Kingdom
Start 03/2010 
End 07/2010
 
Title Protein Production Methods 
Description The facility has allowed us to develop improved and quality controlled methods for protein production and expression for a range of prokaryotic and eukaryotic systems. 
Type Of Material Technology assay or reagent 
Year Produced 2009 
Provided To Others? Yes  
Impact Availability of proteins for follow on studies. Widening of user base with the availability of this resource. 
 
Description Cleavable prodrugs for therapy of complement-mediated diseases 
Organisation Cardiff University
Department School of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution Development of methods.
Collaborator Contribution Development of methods for protein expression and assay development.
Impact None to date. Application for funding submitted.
Start Year 2010
 
Description Expression of Casein Kinase i epsilon delta-C-terminus 
Organisation Cardiff University
Country United Kingdom 
Sector Academic/University 
PI Contribution DPFS PPF is working up methods for purification and production of GLP grade proteins.
Collaborator Contribution Beginning of a collaboration that should eventually use the DPFS PPF to produce proteins
Impact None to date, ongoing work
Start Year 2010
 
Description Production of soluble pMHCI for crystallographic, biophysical and cellular studies. 
Organisation Cardiff University
Department School of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution New methods.
Collaborator Contribution Development of methods for protein purification.Established methods for purification of MHCI molecules.
Impact Commercial work, none to date.
Start Year 2010
 
Description Production of soluble pMHCI for crystallographic, biophysical and cellular studies. 
Organisation Cardiff University
Department School of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution New methods.
Collaborator Contribution Development of methods for protein purification.Established methods for purification of MHCI molecules.
Impact Commercial work, none to date.
Start Year 2010
 
Description Recombinant synthesis and purification of discrete human cardiac ryanodine receptor (RyR) domains 
Organisation Cardiff University
Department School of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution Development of protein production and expression methods.
Collaborator Contribution Development of new methods and scientific outputs.
Impact See publications
Start Year 2008
 
Description Reticulocyte enrichment 
Organisation FibroGen, Inc.
Country United States 
Sector Private 
PI Contribution Contract research and methods development.
Collaborator Contribution Everything other than the above
Impact None, Subject to confidentiality agreement.
Start Year 2010
 
Description Small molecule antagonists at the TrkA receptor for the treatment of pain 
Organisation University of Bristol
Department School of Clinical Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution Developments of new methods for protein purification and production
Collaborator Contribution Proteins manufactured for X-ray crystallography of DS domain of TRKA receptor to support a SARTRE devolved DPFS project.
Impact This project is in partnering discussion with a major pharmaceutical company. New IP is being filed for patent at Bristol University.
Start Year 2010
 
Description The identification of biologically important peptides in a low-PH MHC eluate. 
Organisation Immunocore Ltd
Country United Kingdom 
Sector Private 
PI Contribution Contract Research and peptide purification.
Collaborator Contribution Everything other than the above
Impact Confidential methods.
Start Year 2010
 
Description The purification of the transmembrane domain from Ryanodine receptor 
Organisation Cardiff University
Department School of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution Development of methods for protein purification.
Collaborator Contribution New methods development.
Impact see publications
Start Year 2009
 
Description Meetings with potential commercial clients 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Meeting with small groups to discuss potential contract research.

Contracts with Immunocore and FibroGen arose from these presentations/discussions.
Year(s) Of Engagement Activity 2009,2010